Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 31:13:1163768.
doi: 10.3389/fonc.2023.1163768. eCollection 2023.

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Shobana Anpalakhan  1 , Prerana Huddar  2 , Roya Behrouzi  2 , Alessio Signori  3 , Judith Cave  4 , Charles Comins  5 , Alessio Cortellini  6   7 , Alfredo Addeo  8 , Carles Escriu  9 , Hayley McKenzie  4 , Gloria Barone  10 , Lisa Murray  1 , David J Pinato  6   11 , Christian Ottensmeier  12 , Sara Campos  1 , Sethupathi Muthuramalingam  1 , Samuel Chan  1 , Fabio Gomes  2 , Giuseppe L Banna  1
Affiliations

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Shobana Anpalakhan et al. Front Oncol. .

Abstract

Background: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their impact on overall survival (OS) and progression-free survival (PFS), and related clinical factors.

Methods: The Spinnaker study was a retrospective multicentre observational cohort study of patients treated with first-line pembrolizumab plus platinum-based chemotherapy in six United Kingdom and one Swiss oncology centres. Data were collected on patient characteristics, survival outcomes, frequency and severity of irAEs, and peripheral immune-inflammatory blood markers, including the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).

Results: A total of 308 patients were included; 132 (43%) experienced any grade irAE, 100 (32%) Grade 1-2, and 49 (16%) Grade 3-4 irAEs. The median OS in patients with any grade irAES was significantly longer (17.5 months [95% CI, 13.4-21.6 months]) than those without (10.1 months [95% CI, 8.3-12.0 months]) (p<0.001), either if Grade 1-2 (p=0.003) or Grade 3-4 irAEs (p=0.042). The median PFS in patients with any grade irAEs was significantly longer (10.1 months [95% CI, 9.0-11.2 months]) than those without (6.1 months [95% CI, 5.2-7.1 months]) (p<0.001), either if Grade 1-2 (p=0.011) or Grade 3-4 irAEs (p=0.036). A higher rate of irAEs of any grade and specifically Grade 1-2 irAEs correlated with NLR <4 (p=0.013 and p=0.018), SII <1,440 (p=0.029 ad p=0.039), response to treatment (p=0.001 and p=0.034), a higher rate of treatment discontinuation (p<0.00001 and p=0.041), and the NHS-Lung prognostic classes (p=0.002 and p=0.008).

Conclusions: These results confirm survival outcome benefits in patients with irAEs and suggest a higher likelihood of Grade 1-2 irAEs in patients with lower NLR or SII values or according to the NHS-Lung score.

Keywords: immune-related adverse effects; immunotherapy; lung cancer; neutrophil-to-lymphocyte ratio (NLR); non-small cell lung cancer; overall survival; progression free survival; systemic immune-inflammation index (SII).

PubMed Disclaimer

Conflict of interest statement

GB received grant consultancies from Astrazeneca and Astellas Pharma. AC received speaker fees and grant consultancies by Astrazeneca, MSD, IQVIA, OncoC4, and EISAI. AA received consulting fees from BMS, Astrazeneca, Boehringer-Ingelheim, Roche, MSD, Pfizer, Eli Lilly, and Astellas, and speakers fees from Eli Lilly and Astrazeneca. DP received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, and Falk Foundation; travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Avamune, Exact Sciences, Mursla, DaVolterra, and Astra Zeneca; and research funding to institution from MSD and BMS. GB received travel expenses from Novartis. CO reports personal fees from BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overall survival – any grade (A), G1-2 (B), G3-4 (C).
Figure 2
Figure 2
Progression-free survival – any grade (A), G1-2 (B), G3-4 (C).
See this image and copyright information in PMC

References

    1. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic Proc (2008) 83:355–67. doi: 10.4065/83.3.355 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. . The effect of advances in lung-cancer treatment on population mortality. New Engl J Med (2020) 383:640–9. doi: 10.1056/NEJMoa1916623 - DOI - PMC - PubMed
    1. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, et al. . Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol (2021) 16:140–50. doi: 10.1016/j.jtho.2020.09.022 - DOI - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. . Pembrolizumab for the treatment of non–Small-Cell lung cancer. New Engl J Med (2015) 372:2018–28. doi: 10.1056/NEJMoa1501824 - DOI - PubMed

LinkOut - more resources